Humabiologics Launches Affordable Human Collagen to Support Scientific Research

Researchers facing significant funding constraints now have a new resource in their pursuit of scientific discovery. Humabiologics, a biotechnology innovator, has introduced research-grade human collagen designed to provide scientists with high-quality biomaterials at an accessible price point.

The new product, part of the HumaDerm family, offers researchers an ethically sourced alternative to traditional animal-derived biomaterials. By partnering with FDA-registered and AATB-accredited tissue banks, the company utilizes tissues that are not suitable for transplantation but can contribute meaningfully to scientific research.

Mohammad Albanna, the company's founder and CEO, highlighted the critical nature of this development. As federal budget cuts to research grants like NIH and NSF continue to challenge scientific progress, the new collagen provides a cost-effective solution without compromising research quality.

Tim Bertram from the National Science Foundation Piedmont Triad Regenerative Medicine Engine emphasized the significance of this innovation. The human-derived biomaterial eliminates cost barriers that have historically forced researchers to compromise on physiological relevance, potentially accelerating the translation of research into clinical solutions.

The launch builds upon Humabiologics' recent grant from the Piedmont Triad Regenerative Medicine Engine and represents a strategic collaboration with institutions like the Wake Forest Institute for Regenerative Medicine. By offering human biomaterials at prices lower than animal alternatives, the company aims to enable more precise and clinically relevant research in fields such as regenerative medicine, drug testing, tissue modeling, and organ-on-a-chip applications.

This development could have far-reaching implications for scientific research, potentially enabling more researchers to access high-quality biomaterials and pursue innovative studies that more accurately predict human biological responses. By reducing financial barriers, Humabiologics is positioning itself as a key enabler of scientific advancement in an increasingly constrained funding environment.